Press Release
Astellas Announces Changes in Management Structure and Global Function
Tokyo, February 8, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the changes in its top management structure and global function effective April 1, 2017 as below.
Top Management Structure
Top Management
Divisional/Functional Responsibilities
Yoshihiko Hatanaka CEO
Internal Auditing, External Relations, Drug Discovery Research, Pharmaceutial Technology,
Legal, Intellectual Property, AIRM
Kenji Yasukawa CSTO & CCO
Corporate Planning, Product & Portfolio Strategy, Business Development, Japan Sales & Marketing, Asia & Oceania Business, EMEA Operations, Americas Operations, MS
Sef Kurstjens CMO
Dev, PV, MA, RA, CRQA, QA
Chikashi Takeda CFO
Corporate Finance & Control, Accounting & Tax, Corporate Communications, Procurement, Information Systems, RWI
Fumiaki Sakurai CAO & CECO
Healthcare Policy & CSR, General Affairs, Human Resources, Ethics & Compliance, Executive Office
CEO: Chief Executive Officer CSTO: Chief Strategy Officer CCO: Chief Commercial Officer CMO: Chief Medical Officer CFO: Chief Financial Officer
CAO: Chief Administrative Officer
CECO: Chief Ethics & Compliance Officer
AIRM: Astellas Institute for Regenerative Medicine EMEA: Europe, Middle East and Africa
MS: Marketing Strategy Dev: Development
PV: Pharmacovigilance MA: Medical Affairs
RA: Regulatory Affairs
CRQA: Clinical and Research Quality Assurance QA: Quality Assurance
RWI: Real World Informatics and Analytics
Global Function
Enhancement of Legal
To better address the global business environment and assure high-quality legal function across organization, a new global function, "Legal" that will manage the regional legal functions will be established. The General Counsel will report directly to CEO and also serve as a standing member of the Executive Committee.
Enhancement of Intellectual Property
In order to protect our intellectual property and strengthen functional support to internal stakeholders, a new global function, "Intellectual Property" that will manage the regional intellectual property functions will be established. The Head of Intellectual Property will report directly to CEO.
Restructuring of Technology
In order to strengthen its global operations and contract manufacturing organization management, and to enhance administrative structure, Technology will be restructured into new function structure and will be named as "Pharmaceutical Technology" to accurately emphasize its function in the manufacture of pharmaceutical products.
###
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
Contacts for inquiries or additional information:
Astellas Pharma Inc. Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473
Astellas Pharma Inc. published this content on 08 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 08 February 2017 05:11:05 UTC.
Original documenthttps://www.astellas.com/en/corporate/news/pdf/170208_1_Eg.pdf
Public permalinkhttp://www.publicnow.com/view/3FC5C75FA881E886860EBCCA13C1DAB22926C5B4